US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
112 deals · US$144bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Feb 2025 | Instinct Bio Technical Company | – | Relativity Acquisition Sponsor | Merger | Pending | 225.0 | Biotech | Hunter Taubman Fischer & Li (sell-side)Chardan (sell-side)Loeb & Loeb (buy-side)Ogier (buy-side) |
| Jul 2025 | DiamiR Biosciences Corp. | – | Aptorum Group | Merger | Completed | – | Diagnostics+1 | H.C. Wainwright & Co. (sell-side) |
| Oct 2025 | Astria Therapeutics | – | BioCryst Pharmaceuticals | Acquisition | Completed | 700.0 | Biotech+2 | Evercore (sell-side)Sidley Austin (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Oct 2025 | Avidity Biosciences | – | Novartis | Acquisition | Announced | 11,000.0 | Biotech+2 | Goldman Sachs (sell-side)Barclays (sell-side)Kirkland & Ellis (sell-side)Covington & Burling (buy-side)Freshfields (buy-side)Gordon Dyal & Co. (buy-side) |
| Nov 2025 | Aptose Biosciences | – | HS North America | Acquisition | Announced | – | Biotech+2 | Locust Walk (sell-side)Stikeman Elliott (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| 2026 | Calytrix Bio | – | Eli Lilly | Acquisition | Announced | 1,500.0 | Biotech | Centerview Partners (sell-side) |
| 2026 | AttaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 3,800.0 | Biotech+2 | Moelis & Company (sell-side) |
| 2026 | FireFly Biologics | – | J&J | Acquisition | Announced | 1,000.0 | Biotech+1 | Centerview Partners (sell-side) |
| Jan 2026 | Dark Blue Therapeutics | – | Amgen | Acquisition | Completed | 840.0 | Biotech+2 | Goodwin (sell-side)BofA Securities (sell-side) |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Completed | – | Biotech+2 | TD Securities (sell-side)WilmerHale (sell-side)Gordon Dyal & Co. (buy-side)Fenwick & West (buy-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | InduPro Therapeutics | – | Eli Lilly and Company | Stake | Announced | – | Biotech+2 | Freshfields (buy-side) |
| Jan 2026 | RAPT Therapeutics | – | GSK | Acquisition | Announced | 2,200.0 | Biotech+1 | J.P. Morgan (sell-side)Cooley (sell-side)Latham & Watkins (sell-side)Evercore (buy-side)A&O Shearman (buy-side) |
| Jan 2026 | Repare Therapeutics | – | XenoTherapeutics | Acquisition | Completed | – | Biotech+1 | Cooley (sell-side)Stikeman Elliott (sell-side) |
| Feb 2026 | PrimeGen US | – | DT Cloud Star Acquisition | Merger | Announced | 1,500.0 | Biotech+1 | A.G.P./Alliance Global Partners (sell-side)Sichenzia Ross Ference Carmel (sell-side)Loeb & Loeb (buy-side) |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
| Feb 2026 | Faeth Therapeutics | – | Sensei Biotherapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)Lucid Capital Markets (buy-side)Sidley Austin (buy-side) |
| Feb 2026 | Arcellx | – | Gilead Sciences | Acquisition | Announced | 7,800.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Morgan Stanley (buy-side)Ropes & Gray (buy-side)Innisfree M&A (buy-side) |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Mar 2026 | Cullgen | – | Gyre Therapeutics | Acquisition | Pending | 300.0 | Biotech+1 | Mintz (sell-side)Moelis & Company (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Candid Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Mar 2026 | Unleash-owned rights to UIO-524, UIO-525 and UIO-526 | Unleash Immuno Oncolytics | TransCode Therapeutics | Asset sale | Pending | – | Biotech+2 | Tungsten Advisors |
| Mar 2026 | Lisata Therapeutics | – | Kuva Labs | Acquisition | Pending | – | Biotech+2 | Mintz (sell-side)H.C. Wainwright & Co. (sell-side)Goodwin (buy-side)Campaign Management (buy-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Announced | 2,000.0 | Biotech+2 | Goodwin (sell-side)Centerview Partners (sell-side) |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Announced | 1,675.0 | Biotech+1 | Paul, WeissGoodwin (sell-side)Centerview Partners (buy-side) |
| Mar 2026 | Terns Pharmaceuticals | – | Merck & Co. | Acquisition | Announced | 6,700.0 | Biotech+2 | Centerview Partners (sell-side)Freshfields (sell-side)Jefferies (sell-side)Covington & Burling (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Eos SENOLYTIX | – | Pulmatrix | Merger | Announced | – | Biotech+1 | Palladium Capital Group (buy-side)Evolution Venture Partners (sell-side)Wilk Auslander (sell-side)Gemini Valuation Services (buy-side)Haynes Boone (buy-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Announced | 3,150.0 | Biotech+2 | Goodwin (sell-side)J.P. Morgan (sell-side)CMS (sell-side)Centerview Partners (buy-side)Allen & Company (buy-side)Covington & Burling (buy-side)Arnold & Porter (buy-side)Venable (buy-side) |
| Apr 2026 | CrossBridge Bio | – | Eli Lilly and Company | Acquisition | Announced | 300.0 | Biotech+2 | Cooley (sell-side) |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Completed | 413.5 | Biotech+2 | Goodwin (sell-side)Sidley Austin (buy-side)Leerink Partners (sell-side)Lucid Capital Markets (buy-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | Kelonia Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 7,000.0 | Biotech+2 | Goodwin (sell-side)Jefferies (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Ajax Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,300.0 | Biotech+2 | Cooley (sell-side)Kirkland & Ellis (sell-side)Ropes & Gray (buy-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built